Lin Wei-Shiang, Chen Pei-Chih, Yang Cheng-De, Cho EunJung, Hahn Bevra H, Grossman Jennifer, Hwang Kwan-Ki, Chen Pojen P
University of California, Los Angeles, CA 90095-1670, USA.
Arthritis Rheum. 2007 May;56(5):1638-47. doi: 10.1002/art.22522.
To test the hypothesis that some antiphospholipid antibodies (aPL) in patients with the antiphospholipid syndrome (APS) recognize a conformational epitope shared by beta2-glycoprotein I (beta2GPI; the major autoantigen for the antiphospholipid antibodies) and the homologous catalytic domains of several serine proteases (such as thrombin, activated protein C [APC], and plasmin) involved in hemostasis.
We generated 4 new IgG monoclonal aPL (2 screened against beta2GPI, 1 against thrombin, and 1 against protein C) from 2 APS patients. The monoclonal antibodies (mAb) were analyzed for binding to beta2GPI, thrombin, APC, and plasmin, as well as for anticardiolipin antibody (aCL) activity. To demonstrate a shared epitope between beta2GPI and a serine protease, 1 mAb was studied by cross-inhibition analysis.
Both of the IgG anti-beta2GPI mAb bound to thrombin, APC, and plasmin. On the other hand, the 1 anti-thrombin mAb and the 1 anti-protein C mAb also bound to beta2GPI. Moreover, the binding of 1 cross-reactive mAb to beta2GPI was inhibited by alpha-thrombin (which contains only the catalytic domain of thrombin). All 4 mAb displayed aCL activity.
Taken together with the findings that some aCL bind to several serine proteases that participate in hemostasis and share homologous catalytic domains, these data demonstrate that some aCL in APS patients recognize one or more conformational epitopes shared by beta2GPI and the catalytic domains of disease-relevant serine proteases.
检验抗磷脂综合征(APS)患者体内的某些抗磷脂抗体(aPL)识别β2-糖蛋白I(β2GPI;抗磷脂抗体的主要自身抗原)与几种参与止血的丝氨酸蛋白酶(如凝血酶、活化蛋白C [APC]和纤溶酶)的同源催化结构域所共有的构象表位这一假说。
我们从2例APS患者中制备了4种新的IgG单克隆aPL(2种针对β2GPI进行筛选,1种针对凝血酶,1种针对蛋白C)。分析这些单克隆抗体(mAb)与β2GPI、凝血酶、APC和纤溶酶的结合情况,以及抗心磷脂抗体(aCL)活性。为证明β2GPI与丝氨酸蛋白酶之间存在共同表位,通过交叉抑制分析对1种mAb进行了研究。
两种IgG抗β2GPI mAb均与凝血酶、APC和纤溶酶结合。另一方面,1种抗凝血酶mAb和1种抗蛋白C mAb也与β2GPI结合。此外,α-凝血酶(仅包含凝血酶的催化结构域)可抑制1种交叉反应性mAb与β2GPI的结合。所有4种mAb均显示出aCL活性。
结合某些aCL与几种参与止血且具有同源催化结构域的丝氨酸蛋白酶结合的研究结果,这些数据表明APS患者体内的某些aCL识别β2GPI与疾病相关丝氨酸蛋白酶的催化结构域所共有的一个或多个构象表位。